We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 270% below its sector, cheaper than its peers on earnings.
Chongqing Lummy Pharmaceutical Co., Ltd. is a Chinese firm dedicated to the research, development, production, and distribution of a broad spectrum of pharmaceutical products. Its extensive portfolio encompasses treatments for various therapeutic areas, including oncology, infectious diseases (antibacterial, antiviral, and antifungal), liver support, and endocrine disorders. The company also develops and markets medications for the digestive, immune, blood, cardiovascular, and nervous systems, in addition to traditional Chinese patent medicines. Further offerings include electrolyte and acid-base balancing agents, nutritional supplements, large volume parenteral solutions, American ginseng preparations, and active pharmaceutical ingredients. Established in 1999, the company's headquarters are located in Chongqing, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300006.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
